Ket

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ket

Property Description
Active ingredient Ketorolac Tromethamine
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic compound
Common forms Tablets, Injection solution, Ophthalmic solution
General purpose Potent, short-term pain relief

Ketorolac is a potent, synthetic compound containing the active substance, Ketorolac Tromethamine. It is scientifically classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is clinically recognized for its effective non-opioid analgesic properties. This positioning confirms the drug's role in offering significant pain control without engaging the central nervous system receptors associated with narcotics. Ketorolac is differentiated within the NSAID class because it is utilized when pain requires a level of efficacy substantially greater than standard, easily accessible pain relievers.


Composition and Available Forms of Ketorolac

The medication is supplied as a single-ingredient product, leveraging the high potency of the Ketorolac Tromethamine compound. Its utility is significantly extended through various pharmaceutical preparations, enabling both systemic and topical applications. Common forms include tablets for oral use, a solution for injection utilized for rapid parenteral administration in hospital settings, and specialized ophthalmic solutions (eye drops). This diverse range of forms, from solid excipients in tablets to an aqueous solution base for injections, ensures the drug can be appropriately delivered to achieve either general body relief or localized treatment.


Ketorolac’s Therapeutic Role and Core Benefit

The principal benefit of Ketorolac is its capacity to deliver strong and effective relief for acute, moderate to severe pain in short-term management scenarios. Its effectiveness is recognized within pharmacological research and clinical experience, confirming its dual capability to provide both analgesic and anti-inflammatory actions. The drug’s benefit stems from its ability to interrupt specific enzyme pathways crucial for producing substances that signal pain and inflammation. This powerful, targeted mechanism offers a highly valuable non-narcotic option for acute pain control.

What side effects are possible with Ket?

Possible Side Effects and Safety Information for Ket

The safety profile for Ket (Ketamine hydrochloride) is primarily documented around its effects on the central nervous and cardiovascular systems, as per governmental regulatory documents.

Key Adverse Reactions and Organ Systems

System-Organ Class Key Adverse Reactions
Cardiovascular Hemodynamic instability (elevated blood pressure and pulse rate are frequent, though hypotension/bradycardia can occur).
Psychiatric/Nervous Emergence reactions (e.g., vivid dreams, hallucinations, delirium, confusional states) are the most common adverse effects, typically resolving within a few hours.
Respiratory Respiratory depression or apnea may occur, especially with high dosage or too rapid intravenous administration.
Genitourinary Lower urinary tract symptoms, including cystitis, have been reported primarily with prolonged or high-dose exposure.

Serious Safety Considerations and Restrictions

Serious Adverse Reactions documented in regulatory sources include Hemodynamic Instability, Respiratory Depression, Drug-Induced Liver Injury, and an Increase in Cerebrospinal Fluid Pressure. The drug is formally contraindicated in patients where a significant rise in blood pressure would pose a serious hazard (e.g., uncontrolled hypertension) or in those with known hypersensitivity.

Population-Specific Warnings include the risk of Pediatric Neurotoxicity—long-term cognitive deficits—when exposure is prolonged (e.g., longer than three hours) in children le 3 years of age. Use during pregnancy, labor, and delivery is generally avoided based on animal data suggesting potential harm to the fetus.

Safety Monitoring requires continuous monitoring of vital signs and cardiac function during administration. Resuscitative equipment for supportive ventilation must be immediately available. The intravenous dose must be administered over a period of 60 seconds to mitigate the risk of respiratory depression and enhanced pressor response.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the manifestations of ketorolac overdose as extensions of known adverse effects. Documented signs typically involve the gastrointestinal system, including epigastric pain, nausea, vomiting, and gastrointestinal hemorrhage, alongside central nervous system effects such as lethargy and disorientation. While these presentations may be reversible with supportive measures, severe and life-threatening outcomes have been reported, necessitating urgent medical intervention. These serious complications, consistent with NSAID toxicity, include acute renal failure, respiratory depression, and coma.


Emergency Actions and Management

Regulatory agencies strictly mandate that individuals seek emergency medical help right away upon suspicion of an overdose. Immediate contact with emergency services is required if the person has collapsed, had a seizure, is experiencing trouble breathing, or can't be awakened. There is no specific antidote known for ketorolac overdose. Management is defined as symptomatic and supportive treatment, including the potential use of gastric lavage and activated charcoal following recent oral ingestion. Close hospital monitoring, particularly of renal function, is required until the patient is stable due to the severe risks involved.

Therapeutic Uses of Ket

Ket is primarily used to help manage severe, acute pain where typical pain management strategies have been unsuccessful. It is commonly administered in hospital or emergency settings to provide temporary relief for patients experiencing intense discomfort. Clinical scenarios where Ket may be utilized include pain associated with major surgical procedures, trauma, or certain procedures requiring sedation or analgesia.

The medication may help modulate the severity of symptoms across several challenging pain categories, which include neuropathic pain, breakthrough cancer pain, and pain requiring rapid stabilization. It may contribute to the patient’s overall functional improvement by reducing debilitating discomfort and allowing for essential medical treatments to proceed.

Quick Fact: May help manage severe acute pain.

Eligibility and Restrictions for Use

Eligibility Profile for Ketorolac (Ket)

The official regulatory profile for Ketorolac Tromethamine defines strict population eligibility, primarily due to its classification as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID) with associated risks of serious gastrointestinal, renal, and bleeding events. Use is generally restricted to adult patients for short-term pain management.

Absolute Contraindications

Ketorolac is CONTRAINDICATED in several high-risk groups, including patients with:

  • Active peptic ulcer disease or a history of GI bleeding or perforation.
  • Advanced renal impairment or conditions causing volume depletion risk.
  • Suspected or confirmed cerebrovascular bleeding or other bleeding disorders.
  • Known hypersensitivity to Ketorolac, aspirin, or other NSAIDs.
  • Treatment for peri-operative pain in the setting of CABG surgery.

Restricted and Non-Eligible Groups

The medicine is CONTRAINDICATED for use during labor and delivery and in nursing mothers. Use should be avoided in late pregnancy (starting at 30 weeks gestation). For older adults (ge 65 years) and patients weighing less than 50 kg, reduced dosages and close monitoring are mandatory. Ketorolac oral tablets are not indicated for use in pediatric patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ketorolac Tromethamine highlights several restricted and contraindicated combinations documented in government regulatory sources (e.g., FDA, EMA). This structure emphasizes additive toxicity risks and alterations in renal clearance.

Formal Contraindications

Co-administration is prohibited with Aspirin or other NSAIDs due to the cumulative risk of serious NSAID-related side effects. The product is also formally contraindicated with Probenecid and Oxpentifylline (Pentoxifylline). Use is additionally prohibited in patients receiving full therapeutic doses of Anticoagulants (e.g., Warfarin, Heparin) due to the heightened risk of serious bleeding.

Clinically Significant Interactions

Interaction statements cite the potential for elevated plasma concentrations of certain co-administered drugs. For instance, Lithium and Methotrexate plasma levels may increase due to a reduction in their renal clearance. The combination with Corticosteroids and SSRIs carries an officially documented additive risk of serious gastrointestinal events and bleeding, respectively. Concomitant use with Diuretics or ACE Inhibitors/ARBs may reduce their effectiveness and increase the risk of renal damage.

Population-Specific and Substance Constraints

Official labeling notes that elderly patients may exhibit reduced clearance of Ketorolac. The drug is strictly contraindicated in patients with advanced renal impairment. Finally, the consumption of alcohol is associated with an increased risk of gastrointestinal bleeding when combined with this product.

Mechanism of Action

How Ket Works

Ketorolac Tromethamine acts via the non-selective competitive inhibition of the Cyclooxygenase (COX) enzymes: specifically, the constitutive COX-1 and the inducible COX-2 isoforms. The active S-enantiomer blocks the binding site of these enzymes, interrupting the initial step of the arachidonic acid cascade and reducing the formation of prostanoids, primarily Prostaglandin E2 (PGE2). This inhibition modulates biochemical pathways that mediate localized tissue responses.

By suppressing PGE2, the mechanism reduces the excitability of peripheral nociceptors, which are sensory neurons. This alters the characteristics of afferent signaling. The drug also crosses the blood-brain barrier to modulate enzyme activity within the Central Nervous System, where the reduction of hypothalamic PGE2 allows the central thermoregulatory set-point to normalize. This non-selective mechanism, however, also blocks the COX-1-mediated synthesis of prostaglandins essential for homeostatic physiological functions, defining an inherent mechanistic constraint on continuous modulation.

Dosage and Administration Information

Administration and Dosing of Ketorolac (Ket)

Ketorolac is a medicine governed by strict, short-term usage instructions specified in official prescribing information. Its administration is defined by the route, specific dose limits for different patient groups, and a mandatory maximum duration of use.

Official Routes and Dosing Regimens

Ketorolac is approved for administration via multiple routes, including Intravenous (IV), Intramuscular (IM), Oral, and Ophthalmic (eye drops) formulations. Oral tablets are intended only as a continuation therapy following initial IV or IM dosing and should not be used as the starting dose.

Patient Group / Route Standard Dosing Frequency Max Total Daily Dose (Systemic)
Standard Adult (IV/IM) (at least 50 kg, < 65 yrs) 30 mg every 6 hours 120 mg
Elderly / Low Weight / Impaired Renal Function 15 mg every 6 hours 60 mg
Oral Continuation 10 mg every 4–6 hours 40 mg

Key Procedural and Time Constraints

The most important constraint governing the systemic use of Ketorolac is the total combined duration of IV, IM, and Oral administration, which must not exceed 5 days in adults. Increasing the dose or frequency beyond the labeled recommendation does not enhance efficacy.

  • IV/IM Administration: The IV bolus injection must be administered over no less than 15 seconds. IM injections should be given slowly and deeply into the muscle.
  • Oral Administration: Tablets may be taken with food or an antacid to lessen potential stomach upset.
  • Ophthalmic Solution: This topical form is generally applied one drop four times a day. When used with other topical eye medications, drops must be administered at least 5 minutes apart.

Recent Clinical Evidence

Ket: Recent Clinical Evidence

Non-Surgical and Emergency Pain

The core body of evidence, including findings from randomized controlled trials (RCTs) and systematic reviews, assessed the medicine's application in short-term systemic pain management for adults. Research has explored the use in adult patients (typically aged 18–65 years) experiencing moderate-to-severe pain, which may include conditions like musculoskeletal strain, certain headaches, and acute flank pain. These trials monitored outcomes related to physical discomfort using standardized scales and tracked the use of other pain medications, such as opioids. Findings describe patterns observed in studies related to changes in reported pain intensity over defined short-term intervals. Data show patterns related to the effect on the measurement of opioid consumption.

Post-Surgical Pain

The research examined the medicine in adult patients following major surgical procedures, including orthopedic and spinal surgeries. Studies explored use during periods of increased symptom activity in the immediate post-operative phase. The outcomes monitored included patient-reported pain scores in the recovery room and the total amount of opioid consumption tracked. Systematic reviews described patterns observed in the studies related to measured outcomes for acute pain. Research also monitored outcomes, such as the overall length of hospital stay (LOS). Findings were mixed regarding outcomes linked to functional measures like LOS. Evidence quality varies across studies due to differences in surgical type and accompanying medications.

Evidence for Topical Ocular Applications

This section describes the structure of specific randomized clinical trials that evaluated the ophthalmic solution. Research has been conducted in conditions involving periods of heightened symptoms, specifically following eye surgery. Double-masked clinical trials were utilized to evaluate the effects in patients who had undergone cataract or corneal refractive procedures. Studies explored short-term symptom changes, monitoring outcomes linked to inflammatory or irritative states and patient-reported perceived discomfort, including pain and itching associated with seasonal allergic conjunctivitis.

Evidence Gaps and Research Uncertainty

Studies on Long-Term Outcomes

The follow-up durations for systemic studies were limited, often restricted to the initial five days of treatment. For the topical solution, study results reflect observation periods generally limited to 14 days. There is limited information for long-term outcomes related to either systemic or topical use. Long-term effects and the possibility of sustained functional outcomes over several months are not fully established.

Evidence in Special Populations

Research highlights that data for certain groups remain insufficient. For example, evidence is limited regarding the use of the systemic form in pediatric populations (children and adolescents). While some studies were observed in these younger groups, certainty remains low, and research is ongoing to establish clearer evidence patterns. The results apply only to the adult populations studied, and findings concerning other groups remain uncertain.

Frequently Asked Questions (FAQ)

Common questions about Ket (FAQ)


Q: How quickly can someone expect Ket to start working after they use it?

A: Studies summarized in regulatory documents indicate that pain relief may begin as early as 30 minutes after the medication is administered. The peak analgesic effect—the time the medicine is working most powerfully—is generally reached within 2 to 3 hours after use.

Q: How long does the effect of Ket typically last?

A: The duration of the pain-relieving effect depends on the specific dose received. Official product information indicates that the mean half-life of the active substance in the body is typically 5 to 6 hours in healthy adults. The half-life refers to the time it takes for the amount of drug in the body to be reduced by half.

Q: What are the most common non-serious side effects associated with Ket?

A: Regulatory labeling reports that the most frequently seen side effects (occurring in 1% to 10% of patients) often involve the gastrointestinal and nervous systems. These common effects include headache, dizziness, drowsiness, nausea, indigestion (dyspepsia), and abdominal pain.

Q: Does taking Ket affect a person's ability to drive or operate machinery?

A: Official adverse reaction reports list dizziness and drowsiness as potential side effects of this medication. Official warnings state that due to the potential for these effects, caution is required when engaging in activities such as driving or operating machinery.

Q: Is Ket habit-forming or does it have the potential for dependence?

A: Ket is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not an opioid or narcotic medicine. Therefore, its mechanism of action does not involve the central nervous system pathways that are typically associated with physical dependence and habit-forming potential.

Q: Why is Ket sometimes referred to by a different name online?

A: The formal name for the active substance is ketorolac tromethamine. Because this medication has been marketed by pharmaceutical companies under various brand names in different countries, people often use multiple names or abbreviations when discussing it online.

Q: Does food or drink change how Ket is absorbed by the body?

A: Official pharmacokinetic studies indicate that if the oral tablets are taken after a high-fat meal, the body's peak concentration of the drug may be reduced and delayed. However, taking the medicine with antacids does not appear to change how much of the drug is absorbed overall.

Q: Is Ket safe to use for older adults (senior population)?

A: Regulatory documents state that patients 65 years or older are at an increased risk of serious adverse events, particularly those affecting the stomach and kidneys. Official guidance reflects that regulatory labels specify the need for reduced dosages and close monitoring in this population.

Q: How does Ket's mechanism compare generally to other medicines for this condition?

A: As an NSAID, Ket works by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. This action contrasts with opioid analgesics, which work by binding to specific receptors in the central nervous system to block pain signals.

Q: Do children ever get prescribed Ket, and if so, for what reasons?

A: Official product information notes that the oral tablets are not indicated for use in children. For the systemic injectable form, regulatory data indicates that it has been studied for managing postoperative pain relief in pediatric patients, although evidence is often limited for these groups.

Q: Does Ket affect sleep patterns?

A: Official regulatory reports list drowsiness as a possible side effect in a noticeable percentage of patients. This effect, which is related to the central nervous system, is something that may potentially interfere with a person's normal sleep patterns.

Q: Is it necessary to inform a surgeon that I am taking Ket before an operation?

A: The medication is contraindicated as an analgesic prior to major surgery because its effect on platelet function increases the risk of post-operative bleeding. Official labeling emphasizes the need for healthcare providers to evaluate the risks of using this drug around the time of surgery.

Q: Are generic versions of Ket available, and are they medically equivalent?

A: Yes, the drug ketorolac is available as a generic medication. The US Food and Drug Administration (FDA) requires that all approved generic drugs demonstrate bioequivalence to the original brand-name drug, meaning they must work the same way in the body.

Q: How long does Ket stay in your system after the last use?

A: The active substance in the medicine is mainly metabolized in the liver and then excreted through the kidneys in the urine. The mean half-life, the time it takes for the concentration to halve, is generally reported to be 5 to 6 hours in healthy adults.

Q: Can Ket cause changes in mood or behavior?

A: Regulatory documents note that rare but serious postmarketing experiences have included changes in mood and behavior such as psychosis and convulsions. These are not common side effects, but they have been reported to authorities.

Q: Does Ket require a special prescription or monitoring from a doctor?

A: Ketorolac is a prescription-only drug in the United States. Regulatory documents state that when the injection is administered, continuous monitoring of the patient's vital signs and cardiac function is required.

Q: Is Ket available over the counter anywhere in the world?

A: In the United States, official product information classifies ketorolac as prescription-only (Rx-only). Its potent nature and specific safety restrictions typically prevent it from being sold over the counter.

Q: Are there specific symptoms that mean a person should immediately stop taking Ket?

A: Official patient counseling information highlights specific symptoms of serious events, such as stomach bleeding (vomiting blood, black or tarry stools) or allergic reactions (trouble breathing, swelling). The labeling states that if these symptoms occur, immediate emergency medical attention is necessary.

Q: Does Ket carry a Black Box Warning in the official regulatory documents?

A: Yes, US regulatory documents assign a Black Box Warning to this medication. This is a severe warning regarding the serious risks of gastrointestinal bleeding/ulceration, potential cardiovascular thrombotic events (like heart attack or stroke), and the required maximum 5-day duration of use.

Q: If I stop taking Ket, are there any withdrawal symptoms described in official sources?

A: Since the medicine is classified as a non-narcotic NSAID, it does not act on the central nervous system pathways responsible for physical dependence. This means it is not associated with the physical withdrawal symptoms typical of opioid medications.

Q: Is it normal to feel a little dizzy or light-headed when starting Ket?

A: Official adverse event reporting includes dizziness and light-headedness as reported side effects. These effects are associated with the use of the drug.

Q: What should a patient do if they experience a rare but serious side effect from Ket?

A: Official patient counseling instructions state that if symptoms related to serious complications—such as signs of a heart attack, stroke, serious skin reaction, or severe allergic reaction—are experienced, immediate emergency medical attention is required.

Q: Is Ket considered a controlled substance in the United States?

A: No, ketorolac is a Non-Steroidal Anti-Inflammatory Drug (NSAID) used for pain management. It is not classified as a controlled substance by the DEA in the United States.

How should Ket be stored and disposed of?

Storage and Disposal Requirements for Ketorolac

The storage and disposal of Ketorolac Tromethamine must follow the specific conditions mandated by official regulatory labeling to ensure product stability.

Official Storage Conditions

The medicine should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from light and stored away from excessive heat and moisture.

Requirement Rule from Regulatory Labeling
Temperature Store between 20 C and 25 C.
Container Retain in the original carton and keep the container tightly closed.
Prohibition Do not freeze the injection solution.
Child Safety Keep strictly out of the sight and reach of children.

Disposal

Unused or expired Ketorolac must be disposed of according to local regulations and institutional procedures for pharmaceutical waste. Disposal instructions explicitly state that the product should not be poured into drains or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ket found in:

A-Z Index: